Fibromyalgia - 5EU Drug Forecast and Market Analysis to 2023
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>Fibromyalgia</strong> <strong>Market</strong> <strong>5EU</strong> <strong>Drug</strong> <strong>Forecast</strong> <strong>and</strong> <strong>Market</strong> <strong>Analysis</strong> <strong>to</strong> <strong>2023</strong><br />
"The Report <strong>Fibromyalgia</strong> <strong>5EU</strong> <strong>Drug</strong> <strong>Forecast</strong> <strong>and</strong> <strong>Market</strong> <strong>Analysis</strong> <strong>to</strong> <strong>2023</strong> provides<br />
information on pricing, market analysis, shares, forecast, <strong>and</strong> company profiles for<br />
key industry participants. <strong>Market</strong>ResearchReports.biz"<br />
The fibromyalgia market is relatively new <strong>and</strong> not yet established. Three drugs currently<br />
dominate the sales across the 7MM <strong>and</strong> form the core treatment options; Lyrica, Cymbalta<br />
<strong>and</strong> Savella are all approved in the US while only the former is approved in Japan. Since<br />
these drugs are also available in the <strong>5EU</strong> for other indications, they are prescribed as offlabel<br />
therapies. A h<strong>and</strong>ful of other genericized products also provide offlabel usage<br />
including antidepressants, antiepileptics, opioids <strong>and</strong> muscle relaxants. Although Lyrica,<br />
Cymbalta <strong>and</strong> Savella can provide an effective treatment regimen, there are ample<br />
opportunities for the development of alternative treatment choices which can exp<strong>and</strong> the<br />
medications available <strong>to</strong> patients, providing improvement in efficacy, safety <strong>and</strong><br />
compliance. By <strong>2023</strong>, there will be four new entrants <strong>to</strong> the market (Lyrica CR, TNX102<br />
SL, DS5565 <strong>and</strong> TD9855). These new products will help <strong>to</strong> drive market growth <strong>and</strong><br />
offset some of the patent expiries of the leading br<strong>and</strong>s during the forecast period. Despite<br />
these advancements in the treatment l<strong>and</strong>scape, fibromyalgia therapeutic sales growth are<br />
expected <strong>to</strong> be minimal.<br />
GlobalData estimates that the fibromyalgia market across the <strong>5EU</strong> reached sales of<br />
approximately $149.7m in 2013. The EU market is expected <strong>to</strong> grow at a slower rate<br />
compared with the US, owing <strong>to</strong> a lack of approved br<strong>and</strong>s <strong>and</strong> the fact that only one<br />
pipeline product is expected <strong>to</strong> enter the fibromyalgia market during the forecast period.<br />
Download Sample copy of this Report at :<br />
http://www.marketresearchreports.biz/sample/sample/825701<br />
Scope<br />
Overview of <strong>Fibromyalgia</strong> including epidemiology, etiology, symp<strong>to</strong>ms, diagnosis,<br />
pathology <strong>and</strong> treatment guidelines as well as an overview on the competitive l<strong>and</strong>scape.<br />
Detailed information on the key drugs in <strong>5EU</strong> including product description, safety <strong>and</strong><br />
efficacy profiles as well as a SWOT analysis.<br />
Sales forecast for the <strong>to</strong>p drugs in <strong>5EU</strong> from 2013<strong>2023</strong>.<br />
<strong>Analysis</strong> of the impact of key events as well the drivers <strong>and</strong> restraints affecting <strong>5EU</strong><br />
<strong>Fibromyalgia</strong> market.<br />
Reasons <strong>to</strong> buy<br />
Underst<strong>and</strong> <strong>and</strong> capitalize by identifying products that are most likely <strong>to</strong> ensure a robust
eturn<br />
Stay ahead of the competition by underst<strong>and</strong>ing the changing competitive l<strong>and</strong>scape for<br />
<strong>Fibromyalgia</strong>.<br />
Effectively plan your M&A <strong>and</strong> partnership strategies by identifying drugs with the most<br />
promising sales potential<br />
Make more informed business decisions from insightful <strong>and</strong> indepth analysis of drug<br />
performance<br />
Obtain sales forecast for drugs from 2013<strong>2023</strong> in <strong>5EU</strong>.<br />
Follow us on LinkedIn: https://www.linkedin.com/company/marketresearchreportsbiz<br />
Table of Contents<br />
1 Table of Contents<br />
1 Table of Contents 2<br />
1.1 List of Tables 5<br />
1.2 List of Figures 7<br />
2 Introduction 8<br />
2.1 Catalyst 8<br />
2.2 Related Reports 8<br />
2.3 Upcoming Related Reports 9<br />
3 Disease Overview 10<br />
3.1 Etiology <strong>and</strong> Pathophysiology 10<br />
3.1.1 Etiology 10<br />
3.1.2 Pathophysiology 12<br />
3.2 Classification 16<br />
3.3 Symp<strong>to</strong>ms 16<br />
3.4 Quality of Life 17<br />
4 Disease Management 18<br />
4.1 Diagnosis <strong>and</strong> Treatment Overview 18<br />
4.1.1 Diagnosis 18<br />
4.1.2 Treatment Guidelines <strong>and</strong> Leading Prescribed <strong>Drug</strong>s 20<br />
4.1.3 Clinical Practice 22<br />
4.2 France 24<br />
4.3 Germany 25<br />
4.4 Italy 27<br />
4.5 Spain 29<br />
4.6 UK 31<br />
5 Competitive Assessment 34<br />
5.1 Overview 34<br />
5.2 Product Profiles 35<br />
5.2.1 Cymbalta (duloxetine) 35<br />
5.2.2 Savella (milnacipran) 39<br />
5.2.3 Lyrica (pregabalin) 44<br />
5.2.4 Neurontin (gabapentin) 49<br />
About us<br />
<strong>Market</strong>ResearchReports.biz is the most comprehensive collection of market research
eports. <strong>Market</strong>ResearchReports.Biz services are specially designed <strong>to</strong> save time <strong>and</strong> money<br />
for our clients. We are a one s<strong>to</strong>p solution for all your research needs, our main offerings<br />
are syndicated research reports, cus<strong>to</strong>m research, subscription access <strong>and</strong> consulting<br />
services. We serve all sizes <strong>and</strong> types of companies spanning across various industries.<br />
Contact<br />
State Tower<br />
90 Sate Street, Suite 700<br />
Albany, NY 12207<br />
Tel: +15186212074<br />
Website: http://www.marketresearchreports.biz/<br />
E: sales@marketresearchreports.biz